Foghorn Therapeutics Inc. (FHTX)
| Market Cap | 122.32M -50.4% |
| Revenue (ttm) | 112.13M +357.3% |
| Net Income | 9.42M |
| EPS | 0.13 |
| Shares Out | 59.96M |
| PE Ratio | 15.11 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,393,840 |
| Open | 2.080 |
| Previous Close | 1.870 |
| Day's Range | 1.890 - 2.120 |
| 52-Week Range | 1.790 - 7.610 |
| Beta | 3.21 |
| Analysts | Buy |
| Price Target | 4.17 (+104.27%) |
| Earnings Date | Nov 9, 2026 |
About FHTX
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leuk... [Read more]
Financial Performance
In 2025, Foghorn Therapeutics's revenue was $30.91 million, an increase of 36.75% compared to the previous year's $22.60 million. Losses were -$74.28 million, -14.24% less than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for FHTX stock is "Buy." The 12-month stock price target is $4.17, which is an increase of 104.27% from the latest price.
News
Foghorn Therapeutics reports Q3 EPS 80c, consensus (25c)
Reports Q3 revenue $83.54M, consensus $7.1M. Collaboration revenue was $83.5M for the three months ended September 30, compared to $8.2M for the three months ended September 30, 2025. The $75.4M…
Foghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate Update
- Advancing a novel oral small molecule in inflammatory bowel disease (IBD), with potential first-in-human trials targeted by end of 2027
Foghorn Therapeutics Quarterly report: Q3 2026
Foghorn Therapeutics has published its Q3 2026 quarterly earnings report on November 9, 2026.
Foghorn Therapeutics Earnings release: Q3 2026
Foghorn Therapeutics released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in November
WATERTOWN, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a biotechnology company pioneering a new class of medicines against challenging targets in oncology and i...
Foghorn Therapeutics downgraded to In Line from Outperform at Evercore ISI
Evercore ISI downgraded Foghorn Therapeutics (FHTX) to In Line from Outperform with a price target of $3, down from $14. The firm cites the FHD-909 failure for the downgrade. Foghorn’s…
FHTX Investors with $100,000 in Losses Have Opportunity to Join Foghorn Therapeutics Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $FHTX--FHTX Investors with $100,000 in Losses Have Opportunity to Join Foghorn Therapeutics Inc. Fraud Investigation with SBS Law.
Wedbush downgrades Foghorn on end of Lilly collaboration
Wedbush downgraded Foghorn Therapeutics (FHTX) to Neutral from Outperform with a price target of $2, down from $10, after the company and Eli Lilly (LLY) elected not to advance FHD-909…
Foghorn Therapeutics downgraded to Neutral from Outperform at Wedbush
Wedbush analyst Robert Driscoll downgraded Foghorn Therapeutics (FHTX) to Neutral from Outperform with a price target of $2, down from $10.
Foghorn Therapeutics price target lowered to $5 from $12 at Guggenheim
Guggenheim lowered the firm’s price target on Foghorn Therapeutics (FHTX) to $5 from $12 and keeps a Buy rating on the shares after the company announced that they and partner…
Foghorn Therapeutics price target lowered to $5 from $13 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Foghorn Therapeutics (FHTX) to $5 from $13 and keeps a Buy rating on the shares after the company announced the discontinuation of…
Foghorn Therapeutics downgraded to Hold from Buy at TD Cowen
TD Cowen downgraded Foghorn Therapeutics (FHTX) to Hold from Buy without a price target The company and Eli Lilly’s decision not to advance FHD-909 into dose expansion, which in turn…
Foghorn Therapeutics downgraded to Neutral from Buy at BTIG
BTIG downgraded Foghorn Therapeutics (FHTX) to Neutral from Buy after the company announced partner Eli Lilly (LLY) will not advance the FHD-909 program or the SMARCA2 degrader into clinical expansion...
Foghorn Therapeutics downgraded at Citizens after FHD-909 discontinuation
As previously reported, Citizens analyst Silvan Tuerkcan downgraded Foghorn Therapeutics (FHTX) to Market Perform from Outperform after the company and partner Eli Lilly (LLY) announced the discontinu...
Foghorn Therapeutics downgraded to Market Perform from Outperform at Citizens
Citizens downgraded Foghorn Therapeutics (FHTX) to Market Perform from Outperform.
Foghorn Therapeutics price target lowered to $5 from $12 at Stifel
Stifel analyst Laura Prendergast lowered the firm’s price target on Foghorn Therapeutics (FHTX) to $5 from $12 and keeps a Buy rating on the shares. The firm notes the company…
Eli Lilly (LLY) Ends Cancer Development Deal with Foghorn Therapeutics
Foghorn plans to layoff 40% of its staff.
Foghorn Therapeutics drops 44% after scrapping FHD-909 program
Sahres of Foghorn Therapeutics (FHTX) have fallen about 44% to $2.00 in pre-market trading after the company announced that, following a review of clinical data from the Phase 1 dose…
Foghorn to cut 40% of workforce after scrapping Lilly-partnered cancer drug
Foghorn Therapeutics said on Thursday it has discontinued development of an experimental cancer drug partnered with Eli Lilly after it failed to show enough benefit in an early-stage trial.
Foghorn to Slash 40% of Jobs as Lilly Cancer Partnership Falls Apart
Foghorn Therapeutics and Eli Lilly don't plan any future collaborations following the dissolution of a cancer-drug partnership.
Foghorn, Lilly to not advance FHD-909 program, Foghorn to reduce workforce
Foghorn Therapeutics (FHTX) announced that, following a review of clinical data from the Phase 1 dose escalation trial of FHD-909, Foghorn and Lilly (LLY) have decided not to advance the…
Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities
Foghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SMARCA2 degrader program Company to focus resources on wholly owned pipeline, including a Selective EP...
Foghorn Therapeutics reports Q2 EPS (10c), consensus (23c)
Reports Q2 revenue $16.07M, consensus $7.93M. “Our FHD-909 trial in collaboration with Lilly continues to advance through dose escalation, with an initial focus on SMARCA4-mutant NSCLC, a setting wher...
Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update
- FHD-909 (LY4050784) Phase 1 dose-escalation trial advancing as planned with non-small cell lung cancer (NSCLC) as the primary target population - Selective EP300 degraders with potential to treat mu...
Foghorn Therapeutics Quarterly report: Q2 2026
Foghorn Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.